NPM | p14arf | ||
Diffuse nuclear | Nucleolar relocalised | Negative | |
All biopsies | |||
Diffuse nuclear | 78# | 3 | 34# |
Nucleolar relocalised | 5 | 10# | 5 |
Total | 83 | 13 | 39 |
Stages preceding severe dysplasia | |||
Diffuse nuclear | 67¶ | 2 | 14 |
Nucleolar relocalised | 3 | 3 | 2 |
Total | 70 | 5 | 16 |
Stages from severe dysplasia | |||
Diffuse nuclear | 11 | 1 | 20¶ |
Nucleolar relocalised | 2 | 7¶ | 3 |
Total | 13 | 8 | 23 |
#: largest group for each pattern of p14arf expression. ¶:largest group of that table. Nucleolar relocalisations of NPM and p14arf were consistently related (Chi-squared, p<0.001), 77% (10 out of 13) of biopsies with nucleolar p14arf also had NPM relocalised in the nucleoli. Diffuse nuclear NPM staining was observed in 87% (34 out of 39) of p14arf biopsies and 94% (78 out of 83) of biopsies with diffuse nuclear p14arf staining. Results from biopsies preceding and from severe dysplasia illustrate the association between p14arf and NPM before and from the stage of severe dysplasia onwards at which p14arf aberration statistically increases. In biopsies preceding severe dysplasia, the largest group shows diffuse nuclear p14arf and diffuse nuclear NPM expression. In stages from severe dysplasia, the largest group loses p14arf expression and shows nuclear NPM expression. In addition, the number of biopsies with nucleolar relocalised NPM increases and the majority (seven out of eight) also have a nucleolar relocalisation of p14arf. The statistical significance of these data could not be calculated due to the small number of samples.